Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation

Cardiovascular Therapeutics

Volumn 31, Issue 6, 2013, Pages 377-380

  Conde, Diego ^a   Costabel, Juan Pablo ^a   Aragon, Martin ^a   Lambardi, Florencia ^a   Klein, Andrés ^a   Corrales Barbosa, Andrea ^a   Trivi, Marcelo ^a   Giniger, Alberto ^a  

^a INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

Author keywords

Atrial fibrillation; Drugs; Propafenone; Treatment; Vernakalant

Indexed keywords

PROPAFENONE; VERNAKALANT;

ADULT; AGED; ARTICLE; BRADYCARDIA; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENTIAL ANALYSIS; SINGLE DRUG DOSE; SINUS RHYTHM;

ATRIAL FIBRILLATION; DRUGS; PROPAFENONE; TREATMENT; VERNAKALANT;

AGED; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PROPAFENONE; PROSPECTIVE STUDIES; PYRROLIDINES;

EID: 84883863001     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12036     Document Type: Article

References (14)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
2. Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003;14:666-672.
3. Li H, Easley A, Barrington W, Windle J. Evaluation and management of atrial fibrillation in the emergency department. Emerg Med Clin North Am 1998;16:389-403.
4. Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation 2012;125:381-389.
5. Azpitarte J, Alvarez M, Baun O, et al. Value of single oral loading dose of propafenone in converting recent-onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997;18:1649-1654.
6. Blanc J, Voinov C, Maarek M. Comparison of oral loading dose of propafenone and amiodarone for converting recent-onset atrial fibrillation. PARSIFAL Study Group. Am J Cardiol 1999;84:1029-1032.
7. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 1995;108:355-358.
8. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:e269-e367.
9. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-1413.
10. Roy D, Rowe BH, Stiell IG, et al. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol 2004;44:2355-2361.
11. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-1525.
12. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G; AVRO Investigators. A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation. J Am Coll Cardiol 2011;57:313-321.
13. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:652-659.
14. Bash LD, Buono JL, Davies GM, et al. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26:167-179.